Trial Outcomes & Findings for A Silver Lining in the VAD Sky (NCT NCT05163392)

NCT ID: NCT05163392

Last Updated: 2025-05-06

Results Overview

Number of driveline infection per 100 patient-months

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

NA

Target enrollment

25 participants

Primary outcome timeframe

2 year

Results posted on

2025-05-06

Participant Flow

25 patients were enrolled and all met inclusion criteria and were randomized to treatment or placebo

Participant milestones

Participant milestones
Measure
SilverD
The SIlverD arm includes: 1. For standard dressing: a silverlon antimicrobial patch, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be weekly. 2. For sensitive skin dressing: a silverlon antimicrobial patch, Providone/iodine swabs for cleaning, an occlusive dressing with window, and sensitive driveline anchors. The driveline dressing change frequency will be weekly. Silverlon: SIlver-plated biopatch
ControlD
The ControlD arm includes: 1. For standard dressing: No antimicrobial barrier, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96 hours. 2. For sensitive skin dressing: No antimicrobial barrier, Providone/iodine swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96hr. Control: Tegaderm without biopatch
Overall Study
STARTED
14
11
Overall Study
COMPLETED
14
11
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Silver Lining in the VAD Sky

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
SilverD
n=14 Participants
The SIlverD arm includes: 1. For standard dressing: a silverlon antimicrobial patch, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be weekly. 2. For sensitive skin dressing: a silverlon antimicrobial patch, Providone/iodine swabs for cleaning, an occlusive dressing with window, and sensitive driveline anchors. The driveline dressing change frequency will be weekly. Silverlon: SIlver-plated biopatch
ControlD
n=11 Participants
The ControlD arm includes: 1. For standard dressing: No antimicrobial barrier, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96 hours. 2. For sensitive skin dressing: No antimicrobial barrier, Providone/iodine swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96hr. Control: Tegaderm without biopatch
Total
n=25 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
11 Participants
n=5 Participants
10 Participants
n=7 Participants
21 Participants
n=5 Participants
Age, Categorical
>=65 years
3 Participants
n=5 Participants
1 Participants
n=7 Participants
4 Participants
n=5 Participants
Age, Continuous
50 years
STANDARD_DEVIATION 15 • n=5 Participants
45 years
STANDARD_DEVIATION 14 • n=7 Participants
47 years
STANDARD_DEVIATION 14 • n=5 Participants
Sex: Female, Male
Female
0 Participants
n=5 Participants
3 Participants
n=7 Participants
3 Participants
n=5 Participants
Sex: Female, Male
Male
14 Participants
n=5 Participants
8 Participants
n=7 Participants
22 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
7 Participants
n=5 Participants
2 Participants
n=7 Participants
9 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
7 Participants
n=5 Participants
9 Participants
n=7 Participants
16 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
United States
14 Participants
n=5 Participants
11 Participants
n=7 Participants
25 Participants
n=5 Participants
BMI
28.8 kg/m2
STANDARD_DEVIATION 4.6 • n=5 Participants
38.4 kg/m2
STANDARD_DEVIATION 5.1 • n=7 Participants
34.28 kg/m2
STANDARD_DEVIATION 7.4 • n=5 Participants

PRIMARY outcome

Timeframe: 2 year

Number of driveline infection per 100 patient-months

Outcome measures

Outcome measures
Measure
SilverD
n=14 Participants
The SIlverD arm includes: 1. For standard dressing: a silverlon antimicrobial patch, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be weekly. 2. For sensitive skin dressing: a silverlon antimicrobial patch, Providone/iodine swabs for cleaning, an occlusive dressing with window, and sensitive driveline anchors. The driveline dressing change frequency will be weekly. Silverlon: SIlver-plated biopatch
ControlD
n=11 Participants
The ControlD arm includes: 1. For standard dressing: No antimicrobial barrier, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96 hours. 2. For sensitive skin dressing: No antimicrobial barrier, Providone/iodine swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96hr. Control: Tegaderm without biopatch
Driveline Infection Rate
0.51 infections per 100 patient-month
06.28 infections per 100 patient-month

SECONDARY outcome

Timeframe: 2 year

Number of days to first driveline infection

Outcome measures

Outcome measures
Measure
SilverD
n=14 Participants
The SIlverD arm includes: 1. For standard dressing: a silverlon antimicrobial patch, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be weekly. 2. For sensitive skin dressing: a silverlon antimicrobial patch, Providone/iodine swabs for cleaning, an occlusive dressing with window, and sensitive driveline anchors. The driveline dressing change frequency will be weekly. Silverlon: SIlver-plated biopatch
ControlD
n=11 Participants
The ControlD arm includes: 1. For standard dressing: No antimicrobial barrier, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96 hours. 2. For sensitive skin dressing: No antimicrobial barrier, Providone/iodine swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96hr. Control: Tegaderm without biopatch
Time to First Driveline Infection
458 days
Interval 279.0 to 637.0
232 days
Interval 74.0 to 390.0

Adverse Events

SilverD

Serious events: 0 serious events
Other events: 0 other events
Deaths: 3 deaths

ControlD

Serious events: 0 serious events
Other events: 0 other events
Deaths: 2 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Sylvie Baudart

UCSF

Phone: 415-203-4027

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place